Alvogen to acquire 4 Pfizer products

PINE BROOK, N.J. — Alvogen on Wednesday announced that it will acquire a portfolio of four pharmaceutical products in the United States from Pfizer.

Alvogen will acquire three injectable products and one inhaled solution product, the company said. Two of the products, clindamycin injection and acetylcysteine inhalation solution, are on-market. Fresenius will continue to market the latter, with Alvogen receiving profit sharing payments. Alvogen will also acquire two pending abbreviated new drug applications: voriconazole and melphalan injections, which are expected to launch as early as 2016.

“This acquisition supports our strategy to gain exposure to the high growth, injectable segment in the U.S. market,” Robert Wessman, chairman and CEO of Alvogen, said. “These products will complement as well as significantly strengthen our existing portfolio, further enhancing our customer offering. We will be able to leverage our current sales and marketing network to increase market share in the U.S.”

Pfizer’s divestment of the four products was a precondition mandated by the Canadian Competition Bureau for the closing of its acquisition of Hospira.